Literature DB >> 11393754

Dry-distillation of astatine-211 from irradiated bismuth targets: a time-saving procedure with high recovery yields.

S Lindegren1, T Bäck, H J Jensen.   

Abstract

Astatine-211 was produced via the 209Bi(alpha,2n) 211At reaction. The radionuclide was isolated with a novel procedure employing dry-distillation of the irradiated target material. The astatine was condensed as a dry residue in a PEEK-capillary cryotrap. Distillation was completed within 1-2 min with isolation yields of 92 +/- 3%. Subsequent work-up of the nuclide resulted in final recovery yields of 79 +/- 3%.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11393754     DOI： 10.1016/s0969-8043(01)00044-6

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN： 0969-8043            Impact factor:   1.513


  29 in total

Review 1.  Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies.

Authors:  Michael R Zalutsky; David A Reardon; Oscar R Pozzi; Ganesan Vaidyanathan; Darell D Bigner
Journal:  Nucl Med Biol       Date:  2007-05-11       Impact factor: 2.408

2.  Shelf-life of ɛ-lysyl-3-(trimethylstannyl)benzamide immunoconjugates, precursors for 211At labeling of antibodies.

Authors:  Emma Aneheim; Jenny Halleröd; Per Albertsson; Holger Jensen; Stellan Holgersson; Sture Lindegren
Journal:  Cancer Biother Radiopharm       Date:  2015-01-14       Impact factor: 3.099

3.  Stability and in vivo behavior of Rh[16aneS4-diol]211 at complex: a potential precursor for astatine radiopharmaceuticals.

Authors:  Marek Pruszyński; Monika Łyczko; Aleksander Bilewicz; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2014-12-23       Impact factor: 2.408

Review 4.  Astatine-211: production and availability.

Authors:  Michael R Zalutsky; Marek Pruszynski
Journal:  Curr Radiopharm       Date:  2011-07

Review 5.  Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations.

Authors:  Mehran Makvandi; Edouard Dupis; Jonathan W Engle; F Meiring Nortier; Michael E Fassbender; Sam Simon; Eva R Birnbaum; Robert W Atcher; Kevin D John; Olivier Rixe; Jeffrey P Norenberg
Journal:  Target Oncol       Date:  2018-04       Impact factor: 4.493

6.  Unexpected Behavior of the Heaviest Halogen Astatine in the Nucleophilic Substitution of Aryliodonium Salts.

Authors:  François Guérard; Yong-Sok Lee; Kwamena Baidoo; Jean-François Gestin; Martin W Brechbiel
Journal:  Chemistry       Date:  2016-06-15       Impact factor: 5.236

7.  A kit method for the high level synthesis of [211At]MABG.

Authors:  Ganesan Vaidyanathan; Donna J Affleck; Kevin L Alston; Xiao-Guang Zhao; Marc Hens; Duncan H Hunter; John Babich; Michael R Zalutsky
Journal:  Bioorg Med Chem       Date:  2007-03-12       Impact factor: 3.641

Review 8.  Production of [(211)At]-astatinated radiopharmaceuticals and applications in targeted α-particle therapy.

Authors:  François Guérard; Jean-François Gestin; Martin W Brechbiel
Journal:  Cancer Biother Radiopharm       Date:  2012-10-17       Impact factor: 3.099

9.  Streptavidin in antibody pretargeting. 5. chemical modification of recombinant streptavidin for labeling with the alpha-particle-emitting radionuclides 213Bi and 211At.

Authors:  D Scott Wilbur; Donald K Hamlin; Ming-Kuan Chyan; Martin W Brechbiel
Journal:  Bioconjug Chem       Date:  2007-12-12       Impact factor: 4.774

10.  Repeated Intraperitoneal alpha-Radioimmunotherapy of Ovarian Cancer in Mice.

Authors:  Jörgen Elgqvist; Håkan Andersson; Holger Jensen; Helena Kahu; Sture Lindegren; Elisabet Warnhammar; Ragnar Hultborn
Journal:  J Oncol       Date:  2009-10-25       Impact factor: 4.375
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.